UbiVac

UbiVac is a clinical-stage immunotherapy company based in Portland, Oregon, pioneering the development of the world's first Dark Genome-derived cancer immunotherapy. Their lead agent, DPV-001, leverages novel non-mutated shared alternative cancer neoantigens to enhance the immune response in patients with advanced cancer, particularly focusing on adenocarcinoma and squamous cell cancers.

Co-founded by Dr. Bernard A. Fox and aligned with the Earle A. Chiles Research Institute, UbiVac's innovative vaccine technology aims to improve patient outcomes by stimulating robust anti-cancer immunity through groundbreaking research on short-lived neoantigens. The company's approach not only uncovers new cancer targets but also shifts the paradigm in cancer treatment, moving towards off-the-shelf universal cancer vaccines.

Generated from the website